Deferoxamine mesylate
Deferoxamine mesylate (pronounced as de-fer-ox-a-mine mes-i-late) is a medication used to treat iron poisoning and aluminum overload in patients with thalassemia and other conditions. It is a chelating agent that binds to excess iron and aluminum in the body, allowing them to be excreted in the urine.
Etymology
The term "Deferoxamine" is derived from the Latin words "de-" meaning "from", "ferro-" meaning "iron", and "-amine" referring to the chemical group containing nitrogen. "Mesylate" refers to the salt form of the drug, derived from methanesulfonic acid.
Usage
Deferoxamine mesylate is used in the treatment of acute iron intoxication and chronic iron overload due to transfusion-dependent anemias. It is also used to treat aluminum overload in patients with chronic renal failure and in patients undergoing long-term dialysis.
Mechanism of Action
Deferoxamine mesylate acts by binding free iron in the bloodstream, forming a stable complex that is then excreted in the urine. This reduces the amount of iron available for participation in harmful chemical reactions in the body.
Related Terms
Side Effects
Common side effects of deferoxamine mesylate include nausea, vomiting, diarrhea, and injection site reactions. More serious side effects can include allergic reactions, changes in vision, and changes in hearing.
Precautions
Patients should be monitored for signs of allergic reactions while taking deferoxamine mesylate. Regular eye and ear examinations are recommended for patients receiving high doses or long-term treatment.
See Also
External links
- Medical encyclopedia article on Deferoxamine mesylate
- Wikipedia's article - Deferoxamine mesylate
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski